The American Journal of Managed Care

FDA Approves Rucaparib in BRCA-Mutated mCRPC

Rucaparib received FDA approval for BRCA-mutated mCRPC after prior androgen receptor–directed therapy, based on the TRITON3 trial results. The trial demonstrated significant improvement in ...
Medical Xpress

CRISPR screen identifies new regulator of androgen receptor in prostate cancer

A poorly characterized protein, historically thought to be a chaperon or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, ...
ascopubs.org

Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual ...

Overall survival and quality of life with [177Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901).
Healio

Study of androgen therapy for transgender men may lead to new breast cancer treatments

Please provide your email address to receive an email when new articles are posted on . Androgen receptor activation counteracted high levels of ER activity. The findings suggest that androgen ...